Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Feature Review
  • Published:

Pharmacogenomics in type 2 diabetes: oral antidiabetic drugs

The Pharmacogenomics Journal volume 16, pages 399–410 (2016)Cite this article

Subjects

Abstract

Type 2 diabetes mellitus (T2DM) is a fast progressing disease reaching pandemic proportions. T2DM is specifically harmful because of its severe secondary complications. In the course of the disease, most patients require treatment with oral antidiabetic drugs (OADs), for which a relatively large number of different options are available. The growing number of individuals affected by T2DM as well as marked interindividual differences in the response to treatment call for individualized therapeutic regimens that can maximize treatment efficacy and thus reduce side effects and costs. A large number of genetic polymorphisms have been described affecting the response to treatment with OADs; in this review, we summarize the most recent advances in this area of research. Extensive evidence exists for polymorphisms affecting pharmacokinetics and pharmacodynamics of biguanides and sulfonylureas. Data on incretin-based medications as well as the new class of sodium/glucose cotransporter 2 (SGLT2) inhibitors are just starting to emerge. With diabetes being a known comorbidity of several psychiatric disorders, we also review genetic polymorphisms possibly responsible for a common treatment response in both conditions. For all drug classes reviewed here, large prospective trials are necessary in order to consolidate the existing evidence and derive treatment schemes based on individual genetic traits.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. Global status report on noncommunicable diseases 2014. World Health Organization: Geneva, 2015.

  2. World Health Organization Global Health Estimates: Deaths by Cause, Age, Sex and Country, 2000-2012. WHO: Geneva, 2014.

  3. Global status report on noncommunicable diseases 2010. World Health Organization: Geneva, 2011.

  4. Hanefeld M, Pistrosch F, Bornstein SR, Birkenfeld AL . The metabolic vascular syndrome - guide to an individualized treatment. Rev Endocr Metab Disord 2016; 17: 5–17.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Shibasaki T, Takahashi T, Takahashi H, Seino S . Cooperation between cAMP signalling and sulfonylurea in insulin secretion. Diabetes Obes Metab 2014; 16: 118–125.

    Article  CAS  PubMed  Google Scholar 

  6. Aguilar-Bryan L, Bryan J . Molecular biology of adenosine triphosphate-sensitive potassium channels. Endocr Rev 1999; 20: 101–135.

    CAS  PubMed  Google Scholar 

  7. He YY, Zhang R, Shao XY, Hu C, Wang CR, Lu JX et al. Association of KCNJ11 and ABCC8 genetic polymorphisms with response to repaglinide in Chinese diabetic patients. Acta Pharmacol Sin 2008; 29: 983–989.

    Article  CAS  PubMed  Google Scholar 

  8. Javorsky M, Klimcakova L, Schroner Z, Zidzik J, Babjakova E, Fabianova M et al. KCNJ11 gene E23K variant and therapeutic response to sulfonylureas. Eur J Intern Med 2012; 23: 245–249.

    Article  CAS  PubMed  Google Scholar 

  9. Sesti G, Laratta E, Cardellini M, Andreozzi F, Del Guerra S, Irace C et al. The E23K variant of KCNJ11 encoding the pancreatic beta-cell adenosine 5'-triphosphate-sensitive potassium channel subunit Kir6.2 is associated with an increased risk of secondary failure to sulfonylurea in patients with type 2 diabetes. J Clin Endocrinol Metab 2006; 91: 2334–2339.

    Article  CAS  PubMed  Google Scholar 

  10. Shimajiri Y, Yamana A, Morita S, Furuta H, Furuta M, Sanke T . Kir6.2 E23K polymorphism is related to secondary failure of sulfonylureas in non‐obese patients with type 2 diabetes. J Diabetes Investig 2013; 4: 445–449.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Gloyn AL, Hashim Y, Ashcroft SJ, Ashfield R, Wiltshire S, Turner RC . Association studies of variants in promoter and coding regions of beta-cell ATP-sensitive K-channel genes SUR1 and Kir6.2 with Type 2 diabetes mellitus (UKPDS 53). Diabet Med 2001; 18: 206–212.

    Article  CAS  PubMed  Google Scholar 

  12. Feng Y, Mao G, Ren X, Xing H, Tang G, Li Q et al. Ser1369Ala variant in sulfonylurea receptor gene ABCC8 is associated with antidiabetic efficacy of gliclazide in Chinese type 2 diabetic patients. Diabetes Care 2008; 31: 1939–1944.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Zhang H, Liu X, Kuang H, Yi R, Xing H . Association of sulfonylurea receptor 1 genotype with therapeutic response to gliclazide in type 2 diabetes. Diabetes Res Clin Pract 2007; 77: 58–61.

    Article  CAS  PubMed  Google Scholar 

  14. Florez JC, Jablonski KA, Bayley N, Pollin TI, de Bakker PI, Shuldiner AR et al. Diabetes Prevention Program Research Group. TCF7L2 polymorphisms and progression to diabetes in the Diabetes Prevention Program. N Engl J Med 2006; 355: 241–250.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Damcott CM, Pollin TI, Reinhart LJ, Ott SH, Shen H, Silver KD et al. Polymorphisms in the transcription factor 7-like 2 (TCF7L2) gene are associated with type 2 diabetes in the Amish: replication and evidence for a role in both insulin secretion and insulin resistance. Diabetes 2006; 55: 2654–2659.

    Article  CAS  PubMed  Google Scholar 

  16. Melzer D, Murray A, Hurst AJ, Weedon MN, Bandinelli S, Corsi AM et al. Effects of the diabetes linked TCF7L2 polymorphism in a representative older population. BMC Med 2006; 4: 34.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Scott LJ, Bonnycastle LL, Willer CJ, Sprau AG, Jackson AU, Narisu N et al. Association of transcription factor 7-like 2 (TCF7L2) variants with type 2 diabetes in a Finnish sample. Diabetes 2006; 55: 2649–2653.

    Article  CAS  PubMed  Google Scholar 

  18. Zhang C, Qi L, Hunter DJ, Meigs JB, Manson JE, van Dam RM et al. Variant of transcription factor 7-like 2 (TCF7L2) gene and the risk of type 2 diabetes in large cohorts of U.S. women and men. Diabetes 2006; 55: 2645–2648.

    Article  CAS  PubMed  Google Scholar 

  19. Saxena R, Gianniny L, Burtt NP, Lyssenko V, Giuducci C, Sjögren M et al. Common single nucleotide polymorphisms in TCF7L2 are reproducibly associated with type 2 diabetes and reduce the insulin response to glucose in nondiabetic individuals. Diabetes 2006; 55: 2890–2895.

    Article  CAS  PubMed  Google Scholar 

  20. Cauchi S, Meyre D, Dina C, Choquet H, Samson C, Gallina S et al. Transcription factor TCF7L2 genetic study in the French population: expression in human beta-cells and adipose tissue and strong association with type 2 diabetes. Diabetes 2006; 55: 2903–2908.

    Article  CAS  PubMed  Google Scholar 

  21. Humphries SE, Gable D, Cooper JA, Ireland H, Stephens JW, Hurel SJ et al. Common variants in the TCF7L2 gene and predisposition to type 2 diabetes in UK European Whites, Indian Asians and Afro-Caribbean men and women. J Mol Med (Berl) 2006; 84: 1005–1014.

    Article  CAS  Google Scholar 

  22. Groves CJ, Zeggini E, Minton J, Frayling TM, Weedon MN, Rayner NW et al. Association analysis of 6,736 U.K. subjects provides replication and confirms TCF7L2 as a type 2 diabetes susceptibility gene with a substantial effect on individual risk. [published erratum appears in Diabetes 2006; 55: 3635] Diabetes 2006; 55: 2640–2644.

    Article  CAS  PubMed  Google Scholar 

  23. Sladek R, Rocheleau G, Rung J, Dina C, Shen L, Serre D et al. A genome-wide association study identifies novel risk loci for type 2 diabetes. Nature 2007; 445: 881–885.

    Article  CAS  PubMed  Google Scholar 

  24. Kimber CH, Doney AS, Pearson ER, McCarthy MI, Hattersley AT, Leese GP et al. TCF7L2 in the Go-DARTS study: evidence for a gene dose effect on both diabetes susceptibility and control of glucose levels. Diabetologia 2007; 50: 1186–1191.

    Article  CAS  PubMed  Google Scholar 

  25. Helgason A, Pálsson S, Thorleifsson G, Grant SF, Emilsson V, Gunnarsdottir S et al. Refining the impact of TCF7L2 gene variants on type 2 diabetes and adaptive evolution. Nat Genet 2007; 39: 218–225.

    Article  CAS  PubMed  Google Scholar 

  26. Grant SF, Thorleifsson G, Reynisdottir I, Benediktsson R, Manolescu A, Sainz J et al. Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes. Nat Genet 2006; 38: 320–323.

    Article  CAS  PubMed  Google Scholar 

  27. Tong Y, Lin Y, Zhang Y, Yang J, Zhang Y, Liu H et al. Association between TCF7L2 gene polymorphisms and susceptibility to type 2 diabetes mellitus: a large Human Genome Epidemiology (HuGE) review and meta-analysis. BMC Med Genet 2009; 10: 15.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Novellasdemunt L, Antas P, Li VS . Targeting Wnt signaling in colorectal cancer. A Review in the Theme: Cell Signaling: Proteins, Pathways and Mechanisms. Am J Physiol Cell Physiol 2015; 309: C511–C521.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Dessimoz J, Bonnard C, Huelsken J, Grapin-Botton A . Pancreas-specific deletion of beta-catenin reveals Wnt-dependent and Wnt-independent functions during development. Curr Biol 2005; 15: 1677–1683.

    Article  CAS  PubMed  Google Scholar 

  30. Papadopoulou S, Edlund H . Attenuated Wnt signaling perturbs pancreatic growth but not pancreatic function. Diabetes 2005; 54: 2844–2851.

    Article  CAS  PubMed  Google Scholar 

  31. Ni Z, Anini Y, Fang X, Mills G, Brubaker PL, Jin T . Transcriptional activation of the proglucagon gene by lithium and beta-catenin in intestinal endocrine L cells. J Biol Chem 2003; 278: 1380–1387.

    Article  CAS  PubMed  Google Scholar 

  32. Yi F, Brubaker PL, Jin T . TCF-4 mediates cell type-specific regulation of proglucagon gene expression by beta-catenin and glycogen synthase kinase-3beta. J Biol Chem 2005; 280: 1457–1464.

    Article  CAS  PubMed  Google Scholar 

  33. Villareal DT, Robertson H, Bell GI, Patterson BW, Tran H, Wice B et al. TCF7L2 variant rs7903146 affects the risk of type 2 diabetes by modulating incretin action. Diabetes 2010; 59: 479–485.

    Article  CAS  PubMed  Google Scholar 

  34. Shu L, Sauter NS, Schulthess FT, Matveyenko AV, Oberholzer J, Maedler K . Transcription factor 7-like 2 regulates beta-cell survival and function in human pancreatic islets. Diabetes 2008; 57: 645–653.

    Article  CAS  PubMed  Google Scholar 

  35. Pearson ER, Donnelly LA, Kimber C, Whitley A, Doney AS, McCarthy MI et al. Variation in TCF7L2 influences therapeutic response to sulfonylureas: a GoDARTs study. Diabetes 2007; 56: 2178–2182.

    Article  CAS  PubMed  Google Scholar 

  36. Holstein A, Hahn M, Körner A, Stumvoll M, Kovacs P . TCF7L2 and therapeutic response to sulfonylureas in patients with type 2 diabetes. BMC Med Genet 2011; 12: 30.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Javorský M, Babjaková E, Klimčáková L, Schroner Z, Zidzik J, Stolfová M et al. Association between TCF7L2 genotype and glycemic control in diabetic patients treated with gliclazide. Int J Endocrinol 2013; 2013: 374858.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Huang Q, Yin JY, Dai XP, Wu J, Chen X, Deng CS et al. Association analysis of SLC30A8 rs13266634 and rs16889462 polymorphisms with type 2 diabetes mellitus and repaglinide response in Chinese patients. Eur J Clin Pharmacol 2010; 66: 1207–1215.

    Article  CAS  PubMed  Google Scholar 

  39. Holstein A, Beil W, Kovacs P . CYP2C metabolism of oral antidiabetic drugs—impact on pharmacokinetics, drug interactions and pharmacogenetic aspects. Expert Opin Drug Metab Toxicol 2012; 8: 1549–1563.

    Article  CAS  PubMed  Google Scholar 

  40. Zhou K, Donnelly L, Burch L, Tavendale R, Doney AS, Leese G et al. Loss-of-function CYP2C9 variants improve therapeutic response to sulfonylureas in type 2 diabetes: a Go-DARTS study. Clin Pharmacol Ther 2010; 87: 52–56.

    Article  CAS  PubMed  Google Scholar 

  41. Becker ML, Visser LE, Trienekens PH, Hofman A, van Schaik RH, Stricker BH . Cytochrome P450 2C9 *2 and *3 polymorphisms and the dose and effect of sulfonylurea in type II diabetes mellitus. Clin Pharmacol Ther 2008; 83: 288–292.

    Article  CAS  PubMed  Google Scholar 

  42. Swen JJ, Wessels JA, Krabben A, Assendelft WJ, Guchelaar HJ et al. Effect of CYP2C9 polymorphisms on prescribed dose and time-to-stable dose of sulfonylureas in primary care patients with Type 2 diabetes mellitus. Pharmacogenomics 2010; 11: 1517–1523.

    Article  CAS  PubMed  Google Scholar 

  43. Abe T, Kakyo M, Tokui T, Nakagomi R, Nishio T, Nakai D et al. Identification of a novel gene family encoding human liver-specific organic anion transporter LST-1. J Biol Chem 1999; 274: 17159–17163.

    Article  CAS  PubMed  Google Scholar 

  44. Klatt S, Fromm MF, König J . The influence of oral antidiabetic drugs on cellular drug uptake mediated by hepatic OATP family members. Basic Clin Pharmacol Toxicol 2013; 112: 244–250.

    Article  CAS  PubMed  Google Scholar 

  45. Kalliokoski A, Neuvonen M, Neuvonen PJ, Niemi M . Different effects of SLCO1B1 polymorphism on the pharmacokinetics and pharmacodynamics of repaglinide and nateglinide. J Clin Pharmacol 2008; 48: 311–321.

    Article  CAS  PubMed  Google Scholar 

  46. Zhang W, He YJ, Han CT, Liu ZQ, Li Q, Fan L et al. Effect of SLCO1B1 genetic polymorphism on the pharmacokinetics of nateglinide. Br J Clin Pharmacol. 2006; 62: 567–572.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Foretz M, Guigas B, Bertrand L, Pollak M, Viollet B . Metformin: from mechanisms of action to therapies. Cell Metab 2014; 20: 953–966.

    Article  CAS  PubMed  Google Scholar 

  48. Morales DR, Morris AD . Metformin in cancer treatment and prevention. Annu Rev Med 2015; 66: 17–29.

    Article  CAS  PubMed  Google Scholar 

  49. Pernicova I, Korbonits M . Metformin—mode of action and clinical implications for diabetes and cancer. Nat Rev Endocrinol 2014; 10: 143–156.

    Article  CAS  PubMed  Google Scholar 

  50. Lozano E, Herraez E, Briz O, Robledo VS, Hernandez-Iglesias J, Gonzalez-Hernandez A et al. Role of the plasma membrane transporter of organic cations OCT1 and its genetic variants in modern liver pharmacology. Biomed Res Int 2013; 2013: 692071.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Takane H, Shikata E, Otsubo K, Higuchi S, Ieiri I . Polymorphism in human organic cation transporters and metformin action. Pharmacogenomics 2008; 9: 415–422.

    Article  CAS  PubMed  Google Scholar 

  52. Shu Y, Sheardown SA, Brown C, Owen RP, Zhang S, Castro RA et al. Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action. J Clin Invest 2007; 117: 1422–1431.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  53. Shu Y, Brown C, Castro RA, Shi RJ, Lin ET, Owen RP et al. Effect of genetic variation in the organic cation transporter 1, OCT1, on metformin pharmacokinetics. Clin Pharmacol Ther 2008; 83: 273–280.

    Article  CAS  PubMed  Google Scholar 

  54. Tzvetkov MV, Vormfelde SV, Balen D, Meineke I, Schmidt T, Sehrt D et al. The effects of genetic polymorphisms in the organic cation transporters OCT1, OCT2, and OCT3 on the renal clearance of metformin. Clin Pharmacol Ther 2009; 86: 299–306.

    Article  CAS  PubMed  Google Scholar 

  55. Zhou K, Donnelly LA, Kimber CH, Donnan PT, Doney AS, Leese G et al. Reduced-function SLC22A1 polymorphisms encoding organic cation transporter 1 and glycemic response to metformin: a GoDARTS study. Diabetes 2009; 58: 1434–1439.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  56. Christensen MM, Brasch-Andersen C, Green H, Nielsen F, Damkier P, Beck-Nielsen H et al. The pharmacogenetics of metformin and its impact on plasma metformin steady-state levels and glycosylated hemoglobin A1c. Pharmacogenet Genomics 2011; 21: 837–850.

    Article  CAS  PubMed  Google Scholar 

  57. Becker ML, Visser LE, van Schaik RH, Hofman A, Uitterlinden AG, Stricker BH . Genetic variation in the organic cation transporter 1 is associated with metformin response in patients with diabetes mellitus. Pharmacogenomics J 2009; 9: 242–247.

    Article  CAS  PubMed  Google Scholar 

  58. Christensen MM, Pedersen RS, Stage TB, Brasch-Andersen C, Nielsen F, Damkier P et al. A gene-gene interaction between polymorphisms in the OCT2 and MATE1 genes influences the renal clearance of metformin. Pharmacogenet Genomics 2013; 23: 526–534.

    Article  CAS  PubMed  Google Scholar 

  59. Chen Y, Li S, Brown C, Cheatham S, Castro RA, Leabman MK et al. Effect of genetic variation in the organic cation transporter 2 on the renal elimination of metformin. Pharmacogenet Genomics 2009; 19: 497–504.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  60. Song IS, Shin HJ, Shim EJ, Jung IS, Kim WY, Shon JH et al. Genetic variants of the organic cation transporter 2 influence the disposition of metformin. Clin Pharmacol Ther 2008; 84: 559–562.

    Article  CAS  PubMed  Google Scholar 

  61. Li Q, Liu F, Zheng TS, Tang JL, Lu HJ, Jia WP . SLC22A2 gene 808 G/T variant is related to plasma lactate concentration in Chinese type 2 diabetics treated with metformin. Acta Pharmacol Sin 2010; 31: 184–190.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  62. Kashi Z, Masoumi P, Mahrooz A, Hashemi-Soteh MB, Bahar A, Alizadeh A . The variant organic cation transporter 2 (OCT2)-T201M contribute to changes in insulin resistance in patients with type 2 diabetes treated with metformin. Diabetes Res Clin Pract 2015; 108: 78–83.

    Article  CAS  PubMed  Google Scholar 

  63. Terada T, Inui K . Physiological and pharmacokinetic roles of H+/organic cation antiporters (MATE/SLC47A). Biochem Pharmacol 2008; 75: 1689–1696.

    Article  CAS  PubMed  Google Scholar 

  64. Meyer zu Schwabedissen HE, Verstuyft C, Kroemer HK, Becquemont L, Kim RB . Human multidrug and toxin extrusion 1 (MATE1/SLC47A1) transporter: functional characterization, interaction with OCT2 (SLC22A2), and single nucleotide polymorphisms. Am J Physiol Renal Physiol 2010; 298: F997–F1005.

    Article  CAS  PubMed  Google Scholar 

  65. Becker ML, Visser LE, van Schaik RH, Hofman A, Uitterlinden AG, Stricker BH . Genetic variation in the multidrug and toxin extrusion 1 transporter protein influences the glucose-lowering effect of metformin in patients with diabetes: a preliminary study. Diabetes 2009; 58: 745–749.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  66. Becker ML, Visser LE, van Schaik RH, Hofman A, Uitterlinden AG, Stricker BH . Interaction between polymorphisms in the OCT1 and MATE1 transporter and metformin response. Pharmacogenet Genomics 2010; 20: 38–44.

    Article  CAS  PubMed  Google Scholar 

  67. Jablonski KA, McAteer JB, de Bakker PI, Franks PW, Pollin TI, Hanson RL et al. Common variants in 40 genes assessed for diabetes incidence and response to metformin and lifestyle intervention in the diabetes prevention program. Diabetes 2010; 59: 2672–2681.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  68. Tkáč I, Klimčáková L, Javorský M, Fabianová M, Schroner Z, Hermanová H et al. Pharmacogenomic association between a variant in SLC47A1 gene and therapeutic response to metformin in type 2 diabetes. Diabetes Obes Metab 2013; 15: 189–191.

    Article  CAS  PubMed  Google Scholar 

  69. He R, Zhang D, Lu W, Zheng T, Wan L, Liu F et al. SLC47A1 gene rs2289669 G>A variants enhance the glucose-lowering effect of metformin via delaying its excretion in Chinese type 2 diabetes patients. Diabetes Res Clin Pract 2015; 109: 57–63.

    Article  CAS  PubMed  Google Scholar 

  70. Ha Choi J, Wah Yee S, Kim MJ, Nguyen L, Ho Lee J, Kang JO et al. Identification and characterization of novel polymorphisms in the basal promoter of the human transporter, MATE1. Pharmacogenet Genomics 2009; 19: 770–780.

    Article  CAS  PubMed  Google Scholar 

  71. Choi JH, Yee SW, Ramirez AH, Morrissey KM, Jang GH, Joski PJ et al. A common 5'-UTR variant in MATE2-K is associated with poor response to metformin. Clin Pharmacol Ther 2011; 90: 674–684.

    Article  CAS  PubMed  Google Scholar 

  72. Stocker SL, Morrissey KM, Yee SW, Castro RA, Xu L, Dahlin A et al. The effect of novel promoter variants in MATE1 and MATE2 on the pharmacokinetics and pharmacodynamics of metformin. Clin Pharmacol Ther 2013; 93: 186–194.

    Article  CAS  PubMed  Google Scholar 

  73. Zhou K, Bellenguez C, Spencer CC, Bennett AJ, Coleman RL, Tavendale R et al. Common variants near ATM are associated with glycemic response to metformin in type 2 diabetes. Nat Genet 2011; 43: 117–120.

    Article  CAS  PubMed  Google Scholar 

  74. Van Leeuwen N, Nijpels G, Becker ML, Deshmukh H, Zhou K, Stricker BH et al. A gene variant near ATM is significantly associated with metformin treatment response in type 2 diabetes: a replication and meta-analysis of five cohorts. Diabetologia 2012; 55: 1971–1977.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  75. Madiraju AK, Erion DM, Rahimi Y, Zhang XM, Braddock DT, Albright RA et al. Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase. Nature 2014; 510: 542–546.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  76. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA . An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J Biol Chem 1995; 270: 12953–12956.

    Article  CAS  PubMed  Google Scholar 

  77. Yki-Järvinen H . Thiazolidinediones. N Engl J Med 2004; 351: 1106–1118.

    Article  PubMed  Google Scholar 

  78. Evans D, de Heer J, Hagemann C, Wendt D, Wolf A, Beisiegel U et al. Association between the P12A and c1431t polymorphisms in the peroxisome proliferator activated receptor gamma (PPAR gamma) gene and type 2 diabetes. Exp Clin Endocrinol Diabetes 2001; 109: 151–154.

    Article  CAS  PubMed  Google Scholar 

  79. Nissen SE, Wolski K . Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007; 356: 2457–2471.

    Article  CAS  PubMed  Google Scholar 

  80. Nissen SE, Wolski K . Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality. Arch Intern Med 2010; 170: 1191–1201.

    Article  CAS  PubMed  Google Scholar 

  81. Singh S, Loke YK, Furberg CD . Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA 2007; 298: 1189–1195.

    Article  CAS  PubMed  Google Scholar 

  82. Mannucci E, Monami M, Di Bari M, Lamanna C, Gori F, Gensini GF et al. Cardiac safety profile of rosiglitazone: a comprehensive meta-analysis of randomized clinical trials. Int J Cardiol 2010; 143: 135–140.

    Article  PubMed  Google Scholar 

  83. Sanyal AJ, Chalasani N, Kowdley KV, McCullough A, Diehl AM, Bass NM et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 2010; 362: 1675–1685.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  84. Kirchheiner J, Thomas S, Bauer S, Tomalik-Scharte D, Hering U, Doroshyenko O et al. Pharmacokinetics and pharmacodynamics of rosiglitazone in relation to CYP2C8 genotype. Clin Pharmacol Ther 2006; 80: 657–667.

    Article  CAS  PubMed  Google Scholar 

  85. Stage TB, Christensen MM, Feddersen S, Beck-Nielsen H, Brøsen K . The role of genetic variants in CYP2C8, LPIN1, PPARGC1A and PPARγ on the trough steady-state plasma concentrations of rosiglitazone and on glycosylated haemoglobin A1c in type 2 diabetes. Pharmacogenet Genomics 2013; 23: 219–227.

    Article  CAS  PubMed  Google Scholar 

  86. Yeo CW, Lee SJ, Lee SS, Bae SK, Kim EY, Shon JH et al. Discovery of a novel allelic variant of CYP2C8, CYP2C8*11, in Asian populations and its clinical effect on the rosiglitazone disposition in vivo. Drug Metab Dispos 2011; 39: 711–716.

    Article  CAS  PubMed  Google Scholar 

  87. Stringer F, DeJongh J, Scott G, Danhof M . A model-based approach to analyze the influence of UGT2B15 polymorphism driven pharmacokinetic differences on the pharmacodynamic response of the PPAR agonist sipoglitazar. J Clin Pharmacol 2014; 54: 453–461.

    Article  CAS  PubMed  Google Scholar 

  88. Barroso I, Gurnell M, Crowley VE, Agostini M, Schwabe JW, Soos MA et al. Dominant negative mutations in human PPARgamma associated with severe insulin resistance, diabetes mellitus and hypertension. Nature 1999; 402: 880–883.

    Article  CAS  PubMed  Google Scholar 

  89. Koch M, Rett K, Maerker E, Volk A, Haist K, Deninger M et al. The PPARgamma2 amino acid polymorphism Pro 12 Ala is prevalent in offspring of Type II diabetic patients and is associated to increased insulin sensitivity in a subgroup of obese subjects. Diabetologia 1999; 42: 758–762.

    Article  CAS  PubMed  Google Scholar 

  90. Kang ES, Park SY, Kim HJ, Kim CS, Ahn CW, Cha BS et al. Effects of Pro12Ala polymorphism of peroxisome proliferator-activated receptor gamma2 gene on rosiglitazone response in type 2 diabetes. Clin Pharmacol Ther 2005; 78: 202–208.

    Article  CAS  PubMed  Google Scholar 

  91. Hsieh MC, Lin KD, Tien KJ, Tu ST, Hsiao JY, Chang SJ et al. Common polymorphisms of the peroxisome proliferator-activated receptor-gamma (Pro12Ala) and peroxisome proliferator-activated receptor-gamma coactivator-1 (Gly482Ser) and the response to pioglitazone in Chinese patients with type 2 diabetes mellitus. Metabolism 2010; 59: 1139–1144.

    Article  CAS  PubMed  Google Scholar 

  92. Blüher M, Lübben G, Paschke R . Analysis of the relationship between the Pro12Ala variant in the PPAR-gamma2 gene and the response rate to therapy with pioglitazone in patients with type 2 diabetes. Diabetes Care 2003; 26: 825–831.

    Article  PubMed  Google Scholar 

  93. Namvaran F, Azarpira N, Rahimi-Moghaddam P, Dabbaghmanesh MH . Polymorphism of peroxisome proliferator-activated receptor γ (PPARγ) Pro12Ala in the Iranian population: relation with insulin resistance and response to treatment with pioglitazone in type 2 diabetes. Eur J Pharmacol 2011; 671: 1–6.

    Article  CAS  PubMed  Google Scholar 

  94. Ouchi N, Kihara S, Arita Y, Maeda K, Kuriyama H, Okamoto Y et al. Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation 1999; 100: 2473–2476.

    Article  CAS  PubMed  Google Scholar 

  95. Ouchi N, Kihara S, Arita Y, Okamoto Y, Maeda K, Kuriyama H et al. Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-kappaB signaling through a cAMP-dependent pathway. Circulation 2000; 102: 1296–1301.

    Article  CAS  PubMed  Google Scholar 

  96. Birkenfeld AL, Boschmann M, Engeli S, Moro C, Arafat AM, Luft FC et al. Atrial natriuretic peptide and adiponectin interactions in man. PLoS One 2012; 7: e43238.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  97. Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, Pratley RE et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 2001; 86: 1930–1935.

    Article  CAS  PubMed  Google Scholar 

  98. Kang ES, Park SY, Kim HJ, Ahn CW, Nam M, Cha BS et al. The influence of adiponectin gene polymorphism on the rosiglitazone response in patients with type 2 diabetes. Diabetes Care 2005; 28: 1139–1144.

    Article  CAS  PubMed  Google Scholar 

  99. Yang H, Ye E, Si G, Chen L, Cai L, Ye C et al. Adiponectin gene polymorphism rs2241766 T/G is associated with response to pioglitazone treatment in type 2 diabetic patients from southern China. PLoS One 2014; 9: e112480.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  100. Li Z, Peng X, Wu Y, Xia Y, Liu X, Zhang Q . The influence of adiponectin gene polymorphism on the pioglitazone response in the Chinese with type 2 diabetes. Diabetes Obes Metab 2008; 10: 794–802.

    Article  CAS  PubMed  Google Scholar 

  101. Namvaran F, Rahimi-Moghaddam P, Azarpira N, Dabbaghmanesh MH . Polymorphism of adiponectin (45T/G) and adiponectin receptor-2 (795G/A) in an Iranian population: relation with insulin resistance and response to treatment with pioglitazone in patients with type 2 diabetes mellitus. Mol Biol Rep 2012; 39: 5511–5518.

    Article  CAS  PubMed  Google Scholar 

  102. Zhang KH, Huang Q, Dai XP, Yin JY, Zhang W, Zhou G et al. Effects of the peroxisome proliferator activated receptor-γ coactivator-1α (PGC-1α) Thr394Thr and Gly482Ser polymorphisms on rosiglitazone response in Chinese patients with type 2 diabetes mellitus. J Clin Pharmacol 2010; 50: 1022–1030.

    Article  CAS  PubMed  Google Scholar 

  103. Yang M, Huang Q, Wu J, Yin JY, Sun H, Liu HL et al. Effects of UCP2 -866 G/A and ADRB3 Trp64Arg on rosiglitazone response in Chinese patients with Type 2 diabetes. Br J Clin Pharmacol 2009; 68: 14–22.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  104. Drucker DJ . The biology of incretin hormones. Cell Metab 2006; 3: 153–165.

    Article  CAS  PubMed  Google Scholar 

  105. Neumiller JJ . Incretin-based therapies. Med Clin North Am 2015; 99: 107–129.

    Article  PubMed  Google Scholar 

  106. Tasyurek HM, Altunbas HA, Balci MK, Sanlioglu S . Incretins: their physiology and application in the treatment of diabetes mellitus. Diabetes Metab Res Rev 2014; 30: 354–371.

    Article  CAS  PubMed  Google Scholar 

  107. Sathananthan A, Man CD, Micheletto F, Zinsmeister AR, Camilleri M, Giesler PD et al. Common genetic variation in GLP1R and insulin secretion in response to exogenous GLP-1 in nondiabetic subjects: a pilot study. Diabetes Care 2010; 33: 2074–2076.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  108. de Luis DA, Diaz Soto G, Izaola O, Romero E . Evaluation of weight loss and metabolic changes in diabetic patients treated with liraglutide, effect of RS 6923761 gene variant of glucagon-like peptide 1 receptor. J Diabetes Complications 2015; 29: 595–598.

    Article  PubMed  Google Scholar 

  109. de Luis DA, Ovalle HF, Soto GD, Izaola O, de la Fuente B, Romero E . Role of genetic variation in the cannabinoid receptor gene (CNR1) (G1359A polymorphism) on weight loss and cardiovascular risk factors after liraglutide treatment in obese patients with diabetes mellitus type 2. J Investig Med 2014; 62: 324–327.

    Article  CAS  PubMed  Google Scholar 

  110. ‘t Hart LM, Fritsche A, Nijpels G, van Leeuwen N, Donnelly LA, Dekker JM et al. The CTRB1/2 locus affects diabetes susceptibility and treatment via the incretin pathway. Diabetes 2013; 62: 3275–3281.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  111. Kanai Y, Lee WS, You GF, Brown D, Hediger MA . The human kidney low affinity Na+/glucose cotransporter SGLT2. Delineation of the major renal reabsorptive mechanism for D-glucose. J Clin Invest 1994; 93: 397–404.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  112. Rajeev SP, Cuthbertson DJ, Wilding JP . Energy balance and metabolic changes with SGLT2 inhibition. Diabetes Obes Metab 2016; 18: 125–134.

    Article  CAS  PubMed  Google Scholar 

  113. Hoeben E, De Winter W, Neyens M, Devineni D, Vermeulen A, Dunne A . Population pharmacokinetic modeling of canagliflozin in healthy volunteers and patients with type 2 diabetes mellitus. Clin Pharmacokinet 2015; 55: 209–223.

    Article  CAS  Google Scholar 

  114. Enigk U, Breitfeld J, Schleinitz D, Dietrich K, Halbritter J, Fischer-Rosinsky A et al. Role of genetic variation in the human sodium–glucose cotransporter 2 gene (SGLT2) in glucose homeostasis. Pharmacogenomics 2011; 12: 1119–1126.

    Article  CAS  PubMed  Google Scholar 

  115. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015; 373: 2117–2128.

    Article  CAS  PubMed  Google Scholar 

  116. Xiu L, Lin M, Liu W, Kong D, Liu Z, Zhang Y et al. Association of DRD3, COMT, and SLC6A4 gene polymorphisms with type 2 diabetes in Southern Chinese: a hospital-based case-control study. Diabetes Technol Ther 2015; 17: 580–586.

    Article  CAS  PubMed  Google Scholar 

  117. Prasad P, Kumar KM, Ammini AC, Gupta A, Gupta R, Thelma BK . Association of dopaminergic pathway gene polymorphisms with chronic renal insufficiency among Asian Indians with type-2 diabetes. BMC Genet 2008; 9: 26.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  118. Martelle SE, Raffield LM, Palmer ND, Cox AJ, Freedman BI, Hugenschmidt CE et al. Dopamine pathway gene variants may modulate cognitive performance in the DHS-Mind Study. Brain Behav 2016; 6: e00446.

    Article  PubMed  PubMed Central  Google Scholar 

  119. Kleinridders A, Cai W, Cappellucci L, Ghazarian A, Collins WR, Vienberg SG et al. Insulin resistance in brain alters dopamine turnover and causes behavioral disorders. Proc Natl Acad Sci USA 2015; 112: 3463–3468.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  120. Hansen T, Ingason A, Djurovic S, Melle I, Fenger M, Gustafsson O et al. At-risk variant in TCF7L2 for type II diabetes increases risk of schizophrenia. Biol Psychiatry 2011; 70: 59–63.

    Article  CAS  PubMed  Google Scholar 

  121. Alkelai A, Greenbaum L, Lupoli S, Sarner-Kanyas K, Ben-Asher E, Lancet D et al. Association of the type 2 diabetes mellitus susceptibility gene, TCF7L2, with schizophrenia in an Arab-Israeli family sample. PLoS One 2012; 7: e29228.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  122. Winham SJ, Cuellar-Barboza AB, Oliveros A, McElroy SL, Crow S, Colby C et al. Genome-wide association study of bipolar disorder accounting for effect of body mass index identifies a new risk allele in TCF7L2. Mol Psychiatry 2014; 19: 1010–1016.

    Article  CAS  PubMed  Google Scholar 

  123. Mulder H, Herder A, Wilmink FW, Tamminga WJ, Belitser SV, Egberts AC . The impact of cytochrome P450-2D6 genotype on the use and interpretation of therapeutic drug monitoring in long-stay patients treated with antidepressant and antipsychotic drugs in daily psychiatric practice. Pharmacoepidemiol Drug Saf 2006; 15: 107–114.

    Article  CAS  PubMed  Google Scholar 

  124. Bacq A, Balasse L, Biala G, Guiard B, Gardier AM, Schinkel A et al. Organic cation transporter 2 controls brain norepinephrine and serotonin clearance and antidepressant response. Mol Psychiatry 2012; 17: 926–939.

    Article  CAS  PubMed  Google Scholar 

  125. Zhang F, Xu Y, Liu P, Fan H, Huang X, Sun G et al. Association analyses of the interaction between the ADSS and ATM genes with schizophrenia in a Chinese population. BMC Med Genet 2008; 9: 119.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  126. Hamilton G, Proitsi P, Jehu L, Morgan A, Williams J, O'Donovan MC et al. Candidate gene association study of insulin signaling genes and Alzheimer's disease: evidence for SOS2, PCK1, and PPARgamma as susceptibility loci. Am J Med Genet B Neuropsychiatr Genet 2007; 144b: 508–516.

    Article  CAS  PubMed  Google Scholar 

  127. Heun R, Kolsch H, Ibrahim-Verbaas CA, Combarros O, Aulchenko YS, Breteler M et al. Interactions between PPAR-alpha and inflammation-related cytokine genes on the development of Alzheimer's disease, observed by the Epistasis Project. Int J Mol Epidemiol Genet 2012; 3: 39–47.

    CAS  PubMed  PubMed Central  Google Scholar 

  128. Kolsch H, Lehmann DJ, Ibrahim-Verbaas CA, Combarros O, van Duijn CM, Hammond N et al. Interaction of insulin and PPAR-alpha genes in Alzheimer's disease: the Epistasis Project. J Neural Transm (Vienna 2012; 119: 473–479.

    Article  CAS  Google Scholar 

  129. Schroeder C, Birkenfeld AL, Mayer AF, Strempel S, Tank T, Diedrich A et al. Norepinephrine transporter inhibition prevents tilt-induced presyncope. J Am Coll Cardiol 2006; 48: 516–522.

    Article  CAS  PubMed  Google Scholar 

  130. Engelmann J, Manuwald U, Rubach C, Kugler J, Birkenfeld AL, Hanefeld M et al. Determinants of mortality in patients with type 2 diabetes: a review. Rev Endocr Metab Disord 2016; 17: 129–137.

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

KI receives funding from the National Institute for Health Research (NIHR) Mental Health Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King’s College London. CK receives funding from Novo Nordisk UK Research Foundation and the NIHR Biomedical Research Centre for Mental Health at South London. ALB receives funding from the German Research Foundation (DFG, BI1292/4-2).

Author information

Authors and Affiliations

  1. Department of Endocrinology, Diabetes and Nutrition, Charite–University School of Medicine, Berlin, Germany

    M A Daniels

  2. Institute of Psychiatry, Psychology and Neuroscience, King’s College London, London, UK

    C Kan & K Ismail

  3. Medical Clinic III, Universitätsklinikum ‘Carl Gustav Carus’, Technische Universität Dresden, Germany

    D M Willmes, F Pistrosch, S R Bornstein & A L Birkenfeld

  4. Paul Langerhans Institute Dresden of the Helmholtz Center Munich at University Hospital and Faculty of Medicine, Technische Universität Dresden, Dresden, Germany

    D M Willmes, F Pistrosch, S R Bornstein & A L Birkenfeld

  5. German Center for Diabetes Research (DZD e.V.), Neuherberg, Germany

    D M Willmes, S R Bornstein & A L Birkenfeld

  6. Competence Center for Metabolic Vascular Medicine Prof. Hanefeld, GWT-TUD GmbH, Dresden, Germany

    F Pistrosch & A L Birkenfeld

  7. Section of Diabetes and Nutritional Sciences, King’s College London, London, UK

    D Hopkins, G Mingrone, S R Bornstein & A L Birkenfeld

  8. Department of Internal Medicine, Catholic University, Rome, Italy

    G Mingrone

Authors
  1. M A Daniels
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. C Kan
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. D M Willmes
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. K Ismail
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. F Pistrosch
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. D Hopkins
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. G Mingrone
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. S R Bornstein
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. A L Birkenfeld
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A L Birkenfeld.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

PowerPoint slides

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Daniels, M., Kan, C., Willmes, D. et al. Pharmacogenomics in type 2 diabetes: oral antidiabetic drugs. Pharmacogenomics J 16, 399–410 (2016). https://doi.org/10.1038/tpj.2016.54

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/tpj.2016.54

This article is cited by

Search

Advanced search

Quick links